Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Gill

Showing results (111-120 of 120) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 120 results.
American Journal of Hematology|January 1, 1980
The Pennsylvania hemophilia program 1973-1978M E Eyster, J H Lewis, S S Shapiro, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 20, 2019
BDNF is a mediator of glycolytic fiber-type specification in mouse skeletal muscleJulien Delezie, Martin Weihrauch, Geraldine Maier, et al.
Investigational New Drugs|December 2, 2010
Multicenter, randomized phase II trial of bevacizumab plus folinic acid, fluorouracil, gemcitabine (FFG) versus bevacizumab plus folinic acid, fluorouracil, oxaliplatin (FOLFOX4) as first-line therapy for patients with advanced colorectal cancerStefan Madajewicz, David M Waterhouse, Paul S Ritch, et al.
Methods in Enzymology|September 16, 2000
3-Hydroxy-3-methylglutaryl-CoA reductaseV W Rodwell, M J Beach, K M Bischoff, et al.
Plos Genetics|April 5, 2014
Protein quantitative trait loci identify novel candidates modulating cellular response to chemotherapyAmy L Stark, Ronald J Hause, Lidija K Gorsic, et al.
American Journal of Human Genetics|August 5, 2014
Identification and validation of genetic variants that influence transcription factor and cell signaling protein levelsRonald J Hause, Amy L Stark, Nirav N Antao, et al.
Investigational New Drugs|August 29, 2009
Gemcitabine plus enzastaurin or single-agent gemcitabine in locally advanced or metastatic pancreatic cancer: results of a phase II, randomized, noncomparative studyDonald A Richards, Paul R Kuefler, Carlos Becerra, et al.
Gynecologic Oncology|October 8, 2011
Phase III trial of induction gemcitabine or paclitaxel plus carboplatin followed by paclitaxel consolidation in ovarian cancerAlan N Gordon, Michael Teneriello, Mike F Janicek, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 19, 2008
Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trialWilliam Small, Jordan Berlin, Gary M Freedman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 19, 2010
Phase III trial of gemcitabine plus docetaxel versus capecitabine plus docetaxel with planned crossover to the alternate single agent in metastatic breast cancerA D Seidman, A Brufsky, R H Ansari, et al.
Pageof 12

Showing results (111-120 of 120) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 120 results.
American Journal of Hematology|January 1, 1980
The Pennsylvania hemophilia program 1973-1978M E Eyster, J H Lewis, S S Shapiro, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 20, 2019
BDNF is a mediator of glycolytic fiber-type specification in mouse skeletal muscleJulien Delezie, Martin Weihrauch, Geraldine Maier, et al.
Investigational New Drugs|December 2, 2010
Multicenter, randomized phase II trial of bevacizumab plus folinic acid, fluorouracil, gemcitabine (FFG) versus bevacizumab plus folinic acid, fluorouracil, oxaliplatin (FOLFOX4) as first-line therapy for patients with advanced colorectal cancerStefan Madajewicz, David M Waterhouse, Paul S Ritch, et al.
Methods in Enzymology|September 16, 2000
3-Hydroxy-3-methylglutaryl-CoA reductaseV W Rodwell, M J Beach, K M Bischoff, et al.
Plos Genetics|April 5, 2014
Protein quantitative trait loci identify novel candidates modulating cellular response to chemotherapyAmy L Stark, Ronald J Hause, Lidija K Gorsic, et al.
American Journal of Human Genetics|August 5, 2014
Identification and validation of genetic variants that influence transcription factor and cell signaling protein levelsRonald J Hause, Amy L Stark, Nirav N Antao, et al.
Investigational New Drugs|August 29, 2009
Gemcitabine plus enzastaurin or single-agent gemcitabine in locally advanced or metastatic pancreatic cancer: results of a phase II, randomized, noncomparative studyDonald A Richards, Paul R Kuefler, Carlos Becerra, et al.
Gynecologic Oncology|October 8, 2011
Phase III trial of induction gemcitabine or paclitaxel plus carboplatin followed by paclitaxel consolidation in ovarian cancerAlan N Gordon, Michael Teneriello, Mike F Janicek, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 19, 2008
Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trialWilliam Small, Jordan Berlin, Gary M Freedman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 19, 2010
Phase III trial of gemcitabine plus docetaxel versus capecitabine plus docetaxel with planned crossover to the alternate single agent in metastatic breast cancerA D Seidman, A Brufsky, R H Ansari, et al.
Pageof 12